Contact
searchSearch
HMP Global

Follicular Lymphoma

News
Tafasitamab Demonstrates Improved Clinical Benefit Among Patients With Relapsed or Refractory FL
08/10/2026
Rebecca Amrick
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding...
08/10/2026
First Report Managed Care
News
Bispecific Antibodies Linked to Lower Immune Toxicity in Follicular Lymphoma and DLBCL
07/10/2026
Grace Taylor, MS, MA
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest...
07/10/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Using One Bispecific Antibody to Treat R/R DLBCL and FL Can Potentially Reduce Staff Time and Care Costs
04/22/2026
Rebecca Amrick
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals...
04/22/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News

Epcoritamab Plus R2 Shows Promise for R/R FL Treatment 
04/15/2026
Rebecca Amrick
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of epcoritamab and rituximab plus lenalidomide (R2) in treating relapsed/refractory follicular lymphoma (R/R FL) found favorable results for patients.
A study assessing the impact of...
04/15/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
News
Bispecific Antibodies in Non-Hodgkin Lymphoma Show Manageable Safety Profile in Meta-Analysis
04/10/2026
Rebecca Amrick
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in non-Hodgkin lymphoma show manageable safety, with common but mostly low-grade infections and hematologic toxicities.
Bispecific antibodies in...
04/10/2026
First Report Managed Care
News
Epcoritamab Expands Treatment Options in Relapsed or Refractory Follicular Lymphoma
04/08/2026
Hannah Musick
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a promising, subcutaneous bispecific antibody option for relapsed or refractory follicular lymphoma, offering high response rates and a manageable safety profile in heavily pretreated patients.
Epcoritamab is emerging as a...
04/08/2026
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos

What's New?

News
Tafasitamab Demonstrates Improved Clinical Benefit Among Patients With Relapsed or Refractory FL
08/10/2026
Rebecca Amrick
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding tafasitamab to lenalidomide plus rituximab was associated with significantly higher progression-free survival and tolerable safety for patients with relapsed or refractory follicular lymphoma (FL).
A study found that adding...
08/10/2026
First Report Managed Care
News
Bispecific Antibodies Linked to Lower Immune Toxicity in Follicular Lymphoma and DLBCL
07/10/2026
Grace Taylor, MS, MA
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest bispecific antibodies are associated with substantially lower early immune-related toxicities compared with CAR T therapy in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, while infectious...
Real-world data suggest...
07/10/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Using One Bispecific Antibody to Treat R/R DLBCL and FL Can Potentially Reduce Staff Time and Care Costs
04/22/2026
Rebecca Amrick
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals...
04/22/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use